Clinical Trials Logo

Clinical Trial Summary

gpASIT+TM product is based on highly purified allergen fragments obtained from grass pollen. The purpose of this study is to demonstrate the clinical efficacy and safety of a subcutaneous immunotherapy with gpASIT+™ in patients with grass pollen-induced allergic rhinoconjunctivitis compared to placebo.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02560948
Study type Interventional
Source BioTech Tools S.A.
Contact
Status Completed
Phase Phase 3
Start date December 2015
Completion date August 2016

See also
  Status Clinical Trial Phase
Completed NCT00658918 - To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405) Phase 3
Active, not recruiting NCT05960266 - Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study Early Phase 1
Completed NCT00574210 - PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm) Phase 2
Completed NCT00384475 - A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413) Phase 3
Completed NCT06457269 - Evaluating the Potential of Large Language Models for Respiratory Disease Consultations N/A
Completed NCT01506375 - Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant Phase 2
Completed NCT01137357 - Probiotics for Reduction Of Markers In Subjects With Allergy N/A
Completed NCT00261287 - Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416) Phase 3
Completed NCT00659594 - Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406) Phase 3
Active, not recruiting NCT00247520 - Safety and Efficacy Study of rEV131 in Allergic Rhinitis Phase 1/Phase 2
Completed NCT00163514 - Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403) Phase 3
Completed NCT04326309 - Audio Data Collection for Identification and Classification of Coughing
Completed NCT00305487 - Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417) Phase 3
Completed NCT02932774 - Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR) Phase 4
Completed NCT00163488 - Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409) Phase 3
Not yet recruiting NCT03724240 - Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis Phase 3
Completed NCT01660737 - Observational Study With PASCALLERG ® in Patients With Hay Fever
Completed NCT02619331 - Evaluation of High Speed Laser Doppler Imaging Technology N/A
Completed NCT00659503 - Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407) Phase 3
Completed NCT01024608 - Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR) Phase 3